Current and Emerging Concepts for Optimizing Outcomes in HR+/HER2- Breast Cancer: The Role of CDK4/6 Inhibitors


Share

Program Content

Activities

  • Current and Emerging Concepts for Optimizing Outcomes in HR+/HER2- Breast Cancer: The Role of CDK4/6 Inhibitors
    Current and Emerging Concepts for Optimizing Outcomes in HR+/HER2- Breast Cancer: The Role of CDK4/6 Inhibitors
    Expert Insights
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 24, 2021

    Expires: November 23, 2022

    View Activity

Faculty

cover img faculity

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Provided by

ProCE Banner